GSK vs PEN
GSK plc vs Penumbra, Inc. — AI-powered side-by-side comparison
GSK
GSK plc
64
Insufficient Data
VS
PEN
Penumbra, Inc.
67
Buy
| Metric | GSK | PEN |
|---|
| AI Score |
64
|
67
|
| Price |
$50.91
|
$326.07
|
| P/E Ratio |
15.80×
|
79.78×
|
| ROE |
35.0%
|
12.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
73.3%
|
67.8%
|
| Debt / Equity |
1.03×
|
0.14×
|
| Dividend Yield |
3.5%
|
0.0%
|
| RSI (14) |
39.2
|
79.6
|
| Beta |
0.3
|
0.701
|
| Expected Upside |
—
|
+6.3%
|
AI Committee View
Current Innellis committee reasoning for GSK versus PEN.
PEN leads by 3 points.
PEN scores 67/100 (Buy) versus GSK at 64/100 (Insufficient Data).
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical